Compugen (NASDAQ:CGEN – Get Free Report) and Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Earnings and Valuation
This table compares Compugen and Jasper Therapeutics’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compugen | $33.46 million | 4.84 | -$18.75 million | ($0.19) | -9.84 |
| Jasper Therapeutics | N/A | N/A | -$64.46 million | ($5.63) | -4.00 |
Compugen has higher revenue and earnings than Jasper Therapeutics. Compugen is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Profitability
This table compares Compugen and Jasper Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compugen | N/A | -27.75% | -17.57% |
| Jasper Therapeutics | N/A | -64.58% | -56.15% |
Analyst Ratings
This is a summary of current ratings and recommmendations for Compugen and Jasper Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compugen | 0 | 0 | 2 | 0 | 3.00 |
| Jasper Therapeutics | 0 | 0 | 9 | 0 | 3.00 |
Compugen presently has a consensus target price of $4.00, suggesting a potential upside of 113.90%. Jasper Therapeutics has a consensus target price of $64.29, suggesting a potential upside of 185.71%. Given Jasper Therapeutics’ higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Compugen.
Institutional and Insider Ownership
12.2% of Compugen shares are held by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 2.7% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Compugen beats Jasper Therapeutics on 7 of the 11 factors compared between the two stocks.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
About Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
